Clinical Trials Logo

Metastatic Ovarian Cancer clinical trials

View clinical trials related to Metastatic Ovarian Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03634150 Withdrawn - Clinical trials for Triple Negative Breast Cancer

Safety and Efficacy of IV Nerofeā„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Start date: September 6, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b, open-label, non-randomized, Dose Confirmation study. Subjects will be treated, once a week, with IV doses of Nerofe and low dose (20 mg/m2) Doxorubicin (6-8 hours from one another) in consecutive, 28-day cycles.